Physician profile
Stuart Porter
NPI 1285306803
$3,581.53
in general payments reported to CMS, 2019-2025
23 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $754 · 2023: $692 · 2024: $935 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,827.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $661.46 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $387.20 | 2022-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $305.64 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Tris Pharma INC | $244.32 | 2022-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $233.25 | 2022-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $218.03 | 2022-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $214.94 | 2022-2025 | Trintellix |
| Lundbeck LLC | $206.13 | 2022-2025 | Rexulti |
| Bausch Health US, LLC | $167.83 | 2023-2025 | Aplenzin |
| Ironshore Pharmaceuticals INC. | $164.60 | 2022-2024 | Jornay Pm |
| Alkermes, INC. | $161.65 | 2022-2025 | Lybalvi |
| Idorsia Pharmaceuticals US INC | $134.16 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $109.10 | 2022-2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $85.52 | 2022 | |
| Corium, LLC | $71.87 | 2023-2025 | Azstarys |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $61.46 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $33.92 | 2022-2023 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.60 | 2022-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $20.13 | 2025 | Austedo Xr |
| Almatica Pharma LLC | $19.49 | 2023 | Loreev Xr |
| Merck Sharp & Dohme LLC | $18.56 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.67 | 2022 | |
| Noven Therapeutics, LLC | $16.00 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.